A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells
- Department of Biosciences and Nutrition, Karolinska Institutet, Sweden
- Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
- Department of Dermatology, New York University Grossman School of Medicine, United States
- Perlmutter Cancer Center, New York University Grossman School of Medicine, United States
- Sahlgrenska Center for Cancer Research, Sweden
Figures
Figure 1
Targeting Icmt improves survival and aorta and muscle phenotypes of progerin-knock-in mice.
(a) Photograph of 15-week-old littermate female mice. (b) Kaplan-Meier plot showing survival of LmnaG609G/G609Icmthm/hm (n = 3) and LmnaG609G/G609GIcmthm/+ (n = 8) mice; the three double-homozygotes were killed for analyses when all the control mice had died of progeria. (c) Body weight curves of mice in panel B. (d) Number of vascular smooth muscle cell nuclei in medial layer of aortic arch sections. Data are mean of three mice/genotype. (e) Representative photographs of aortic arch sections from panel d. (f) Skeletal muscle fiber cross-sectional diameter. Data are mean of 50 independent muscle cells diameters in M. quadriceps extensor from three mice/genotype. (g) Kaplan-Meier plot showing survival of LmnaG609G/+Icmthm/hm (n = 5) and LmnaG609G/+Icmt+/+ (n = 14) mice. *p<0.05; **p<0.01; ***p<0.005; ****p<0.001; n.s., not significant.
Figure 2 with 2 supplements
C75 inhibits isoprenylcysteine carboxylmethyltransferase (ICMT) activity and increases proliferation and reduces senescence of HGPS cells without affecting nuclear shape.
(a) Chemical structure of compound 75 (C75) and percent ICMT activity remaining after incubation with C75. (b) Western blot showing increased amounts of prelamin A in Hutchinson-Gilford progeria syndrome (HGPS) and wild-type (WT) cells incubated with C75 for 20 days; β tubulin was the loading control. (c) Left, immunofluorescence images showing prelamin A expression in HGPS cells incubated with 5 μM C75 for 20 days and 10 μM farnesyltransferase inhibitor (FTI) for 3 days; the cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Right, quantification of prelamin A staining intensity (n = 2 cell lines and six individual images/cell line). (d) Left, representative nuclei of LAP2β-stained WT cells and HGPS cells incubated with vehicle (Ctrl), 5 μM C75 for 20 days, and 10 μM FTI for 3 days. Right, quantification of misshapen nuclei. Data are mean of ∼1000 nuclei and two independent experiments per cell line and condition. (e–h) Population doubling assays of late-passage HGPS cell lines (e, f), primary Zmpste24–/– mouse fibroblasts (g), and Zmpste24–/–Icmt–/– fibroblasts (h) incubated with vehicle (Ctrl) and C75. (i) Population doubling of WT cells incubated with C75. (j, k) Population doubling assays of a late-passage HGPS cell line incubated with vehicle (Ctrl), lonafarnib, C75, and both drugs. (l–n) Senescence-associated beta-galactosidase (β-gal) staining of WT, HGPS, and Zmpste24–/– fibroblasts incubated with vehicle (Ctrl) and C75 for 20 days. (o, p) Interleukin 6 (IL-6) (o) and CDKN2A (p) expression in cells from experiment in panel m. **p<0.01; ***p<0.001; ****p<0.0001; n.s., not significant.
Figure 2—figure supplement 1
C75 synthesis and absorption, distribution, metabolism, and excretion (ADME) test.
(a) Schematic of the C75 synthesis reactions. (b) Mass spectra of the final product. (c) Nuclear magnetic resonance spectra of C75. (d) Left, schematic of the apparent permeability assay through a layer of Caco-2 cells. Right, quantification of apical-to-basolateral (blue) and basolateral-to-apical (red) absorption rates across a Caco-2 cell layer.
Figure 2—figure supplement 2
C75 increases viability, proliferation, and metabolic rates of Hutchinson-Gilford progeria syndrome (HGPS) cells and reduces reactive oxygen species (ROS) levels and nuclei with high levels of DNA damage.
(a) Western blots showing levels of the RAS oncogene in total lysates (T) and in cytosolic (C) and membrane (M) fractions of late-passage HGPS cells and primary Zmpste24–/– mouse fibroblasts; β-actin was the loading control for cytosolic and total fractions. (b) Western blots showing electrophoretic mobility of the CAAX-protein HDJ2; a farnesyltransferase inhibitor (3-day incubation), but not C75 (20-day incubation), could partially reduce HDJ2 mobility. (c and d) Growth curves from presto blue-based cell viability assays of two HGPS cell lines. (e) Cell cycle analysis of HGPS cells. Data are mean of six technical replicates. (f) Seahorse analyses of basal and maximal respiration, and ATP production. Data are mean of two HGPS cell lines assayed in triplicate. (g) ROS levels in two HGPS cell lines incubated with C75 for 20 days. (h) Western blots showing levels of endoplasmic reticulum stress markers in lysates of two HGPS cell lines incubated with C75 for 20 days; tunicamycin was used as positive control. (i) Western blots showing levels of DNA damage markers in lysates of two HGPS cell lines incubated with C75 for 20 days. (j) Left, quantification of the frequency of γ-H2AX-positive nuclei in wild-type cells and in HGPS cells lines incubated with 5 μM C75 for 20 days. Middle, quantification of nuclei with more than six γ-H2AX-foci HGPS cells incubated with 5 μM C75 for 20 days. Data are mean of two cell lines and triplicate analyses. Right, immunofluorescence images showing γ-H2AX-positive nuclei (red); the nuclei were counterstained with DAPI (blue). *p<0.05; **p<0.01; ***p<0.001; n.s., not significant.
Figure 3
The isoprenylcysteine carboxylmethyltransferase inhibitor C75 disrupts progerin-AKT interactions, increases AKT activation, and mislocalizes progerin from the nuclear membrane to the nucleoplasm.
(a) Western blot showing amounts of phosphorylated and total AKT (a.k.a protein kinase B) in whole-cell lysates of human wild-type (WT) and Hutchinson-Gilford progeria syndrome (HGPS) cells and mouse Zmpste24-deficient fibroblasts. (b, c) Left panels, western blots (WB) showing amounts of phosphorylated and total AKT in WT and HGPS cells (b) and Zmpste24-deficient (c) fibroblasts incubated with C75 for 20–30 days; β tubulin was the loading control. Right panels, quantification of the ratio of phosphorylated and total AKT from densitometry analyses of protein bands. Data are mean of two independent cell lines, each analyzed in duplicate. (d) Immunoprecipitation (IP) and WB analyses showing that C75 disrupts the association between AKT and progerin. The lysates were also used directly for WB with total AKT antibodies (input). (e) WB showing amounts of progerin in HGPS cells incubated with C75 for 20 days. (f) WB showing amounts of progerin remaining in HGPS cells incubated with vehicle and 5 μM C75 for 20 days and then with cycloheximide to stop protein synthesis. (g) Quantification of progerin amounts from the experiment in panel f and two others like it. (h, i) Left panels, WB showing amounts of progerin and prelamin A in nuclear membrane and nucleoplasm fractions of HGPS (h) and Zmpste24-deficient (i) fibroblasts, respectively, incubated with vehicle and 5 μM C75 for 20 days. Lamin B2 and nuclear P84 were loading controls for nuclear membrane and nucleoplasm fractions, respectively. Right panels, quantification of nucleoplasmic progerin/prelamin A from densitometry analyses. *p<0.05; **p<0.01; ***p<0.001.
Author response image 1
Additional files
-
Source data 1
Exact P values.
- https://cdn.elifesciences.org/articles/63284/elife-63284-data1-v2.xlsx
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/63284/elife-63284-transrepform-v2.docx
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells
eLife 10:e63284.
https://doi.org/10.7554/eLife.63284
